Krystal Biotech, Inc. financial data

Symbol
KRYS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2100 Wharton Street, Suite 701, Pittsburgh, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 4, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.07K % -31.7%
Quick Ratio 20.2 %
Debt-to-equity 8.15 % +37%
Return On Equity 6.34 %
Return On Assets 5.87 %
Operating Margin 11.4 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.8M shares +1.97%
Common Stock, Shares, Outstanding 28.8M shares +2%
Entity Public Float 2.8B USD +100%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 28.7M shares +2.4%
Weighted Average Number of Shares Outstanding, Diluted 29.9M shares +3.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 242M USD +880%
Research and Development Expense 51.4M USD +12.3%
General and Administrative Expense 93.9M USD +67.1%
Operating Income (Loss) 27.5M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 29.8M USD -63.1%
Income Tax Expense (Benefit) 2.59M USD
Net Income (Loss) Attributable to Parent 52.4M USD -66.3%
Earnings Per Share, Basic 2.05 USD/shares -67%
Earnings Per Share, Diluted 2.08 USD/shares -67.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 374M USD +0.19%
Cash, Cash Equivalents, and Short-term Investments 588M USD +4.66%
Accounts Receivable, after Allowance for Credit Loss, Current 97.3M USD +944%
Inventory, Net 18.6M USD +252%
Assets, Current 713M USD +22.5%
Property, Plant and Equipment, Net 157M USD -4.53%
Operating Lease, Right-of-Use Asset 6.47M USD -12.1%
Other Assets, Noncurrent 203K USD -28.8%
Assets 982M USD +24.3%
Accounts Payable, Current 5.58M USD +28.6%
Liabilities, Current 89.5M USD +225%
Operating Lease, Liability, Noncurrent 6.18M USD -9.31%
Other Liabilities, Noncurrent 761K USD
Liabilities 96.5M USD +180%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.51M USD
Retained Earnings (Accumulated Deficit) -226M USD +18.8%
Stockholders' Equity Attributable to Parent 886M USD +17.2%
Liabilities and Equity 982M USD +24.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 15.9M USD
Net Cash Provided by (Used in) Financing Activities 10.6M USD +618%
Net Cash Provided by (Used in) Investing Activities -26M USD -829%
Common Stock, Shares Authorized 80M shares 0%
Common Stock, Shares, Issued 28.8M shares +2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 678K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 374M USD +0.19%
Deferred Tax Assets, Valuation Allowance 77M USD -6.69%
Deferred Tax Assets, Gross 91.6M USD +6.74%
Operating Lease, Liability 7.48M USD -10.1%
Depreciation 6.04M USD +33.9%
Payments to Acquire Property, Plant, and Equipment 1.26M USD -76.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 54.3M USD -63.6%
Lessee, Operating Lease, Liability, to be Paid 15M USD -9.46%
Property, Plant and Equipment, Gross 176M USD +0.92%
Operating Lease, Liability, Current 1.29M USD -13.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.28M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.28M USD -17%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.53M USD -8.77%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.3M USD +1.8%
Deferred Tax Assets, Operating Loss Carryforwards 40M USD -24%
Preferred Stock, Shares Issued 2.06M shares 0%
Preferred Stock, Shares Authorized 20M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.33M USD +1.92%
Additional Paid in Capital 1.11B USD +7.31%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 14.6M USD +342%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%